Sunday, August 11, 2019 9:10:43 PM
TherapeuticsMD , Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The firm also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL .
SHORT INTEREST
84.93M 07/15/19
P/E Current
-3.83
P/E Ratio (with extraordinary items)
-3.21
Average Recommendation: BUY
Average Target Price: 10.57
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent TXMD News
- TherapeuticsMD Announces Full Year 2023 Financial Results • Business Wire • 03/29/2024 08:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2023 09:51:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/06/2023 04:36:35 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/17/2023 02:28:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/17/2023 02:27:23 PM
- TherapeuticsMD Announces Third Quarter 2023 Financial Results • Business Wire • 11/14/2023 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 08:22:58 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2023 08:20:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/18/2023 09:18:30 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:15:28 AM
- TherapeuticsMD Announces Second Quarter 2023 Financial Results • Business Wire • 08/14/2023 10:50:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2023 09:29:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2023 09:28:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/19/2023 09:27:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2023 09:20:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/06/2023 08:38:59 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 06/30/2023 12:29:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/29/2023 09:21:32 PM
- TherapeuticsMD Announces First Quarter 2023 Financial Results • Business Wire • 05/15/2023 08:05:00 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM